Market Overview:
The global Cushing's syndrome and acromegaly treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of Cushing's syndrome and acromegaly, rising awareness about these diseases, and technological advancements in the field of diagnosis and treatment. The global Cushing's syndrome and acromegaly treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into glucocorticoid receptor inhibitors, somatostatin analogs/inhibitors, ketoconazole HRA (high-dose regimens), others. Glucocorticoid receptor inhibitors are expected to dominate the global Cushing's syndrome and acromegaly treatment market owing to their high efficacy in treating these diseases. On the basis of application, hospital pharmacies accounted for majority share of revenue generated by this market in 2017; however, retail pharmacies are projected to witness highest growth during forecast period owing to increase in number private clinics across world coupled with growing demand for self-medication among patients diagnosed with chronic diseases such as cancer or diabetes mellitus which often require long-term drug therapy .
Product Definition:
Cushing's Syndrome is a disorder that is caused by an excess of the hormone cortisol. Acromegaly Treatment is the treatment for acromegaly, a condition that results from too much growth hormone.
Glucocorticoid Receptor Inhibitors:
Glucocorticoid receptor inhibitors (GRIs) are a new class of anti-inflammatory drugs that prevent the inflammatory response caused by the body's immune system. They work by blocking certain chemical signals between cells in the immune system and brain, which prevents inflammation. Currently, there are two approved glucocorticoid receptor inhibitors in Europe and North America: Fluticasone propionate (Nasonex) and mongersen (Ubrogepant).
Somatostatin:
Somatostatin is a peptide hormone that controls the release of various hormones from the anterior pituitary gland. It is produced in response to injury or stress and functions to protect the body against harmful stimuli. In addition, it also helps in maintaining normal growth & development, memory, sexual function & fertility as well as regulates digestion and cardiovascular functioning among other functions.
Cushing’s syndrome (CS).
Application Insights:
Based on application, the global market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacy segment dominated the market in 2017 due to a high prevalence of patients suffering from Cushing's syndrome or acromegaly and increasing awareness among healthcare professionals. Hospital based pharma companies are developing drugs specifically designed for this condition which can be used as an alternative to glucocorticoids with less side effects. This has led to an increase in demand for these drugs from various countries around the world including India, Brazil China etc.
The online pharmacy sector is expected to witness significant growth over the forecast period owing to increased accessibility of medicines through internet coupled with growing concerns regarding adverse effects associated with conventional treatment methods such as surgery & radiation therapy etc.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors contributing to its growth. In addition, rise in prevalence of cushing's syndrome and acromegaly is expected to drive regional demand for treatment over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising disposable income coupled with improving healthcare infrastructure in emerging countries such as China & India. Furthermore, growing awareness about early diagnosis will also boost regional growth over the next eight years.
Growth Factors:
- Increasing incidence of Cushing's Syndrome and Acromegaly
- Growing awareness about the diseases and their treatment options
- Rising demand for better and more effective therapies for Cushing's Syndrome and Acromegaly
- Technological advancements in the field of acromegaly treatment 5. Availability of government funding for research on acromegaly
Scope Of The Report
Report Attributes
Report Details
Report Title
Cushing's Syndrome and Acromegaly Treatment Market Research Report
By Type
Glucocorticoid Receptor Inhibitors, Somatostatin, Ketoconazole HRA, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Pfizer, Novartis, Bristol-Myers Squibb, Corcept Therapeutics, HRA Pharma, Ipsen Biopharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
224
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Cushing's Syndrome and Acromegaly Treatment Market Report Segments:
The global Cushing's Syndrome and Acromegaly Treatment market is segmented on the basis of:
Types
Glucocorticoid Receptor Inhibitors, Somatostatin, Ketoconazole HRA, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Bristol-Myers Squibb
- Corcept Therapeutics
- HRA Pharma
- Ipsen Biopharmaceuticals
Highlights of The Cushing's Syndrome and Acromegaly Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Glucocorticoid Receptor Inhibitors
- Somatostatin
- Ketoconazole HRA
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cushing's Syndrome and Acromegaly Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cushing's Syndrome is a disorder caused by an overproduction of cortisol, a hormone that helps control the body's response to stress. Acromegaly is a condition in which the pituitary gland produces too much growth hormone. Treatment for both conditions includes medication and surgery to reduce the amount of cortisol or growth hormone produced.
Some of the major players in the cushing's syndrome and acromegaly treatment market are Pfizer, Novartis, Bristol-Myers Squibb, Corcept Therapeutics, HRA Pharma, Ipsen Biopharmaceuticals.
The cushing's syndrome and acromegaly treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cushing's Syndrome and Acromegaly Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cushing's Syndrome and Acromegaly Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cushing's Syndrome and Acromegaly Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cushing's Syndrome and Acromegaly Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cushing's Syndrome and Acromegaly Treatment Market Size & Forecast, 2020-2028
4.5.1 Cushing's Syndrome and Acromegaly Treatment Market Size and Y-o-Y Growth
4.5.2 Cushing's Syndrome and Acromegaly Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Glucocorticoid Receptor Inhibitors
5.2.2 Somatostatin
5.2.3 Ketoconazole HRA
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cushing's Syndrome and Acromegaly Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cushing's Syndrome and Acromegaly Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Glucocorticoid Receptor Inhibitors
9.6.2 Somatostatin
9.6.3 Ketoconazole HRA
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Glucocorticoid Receptor Inhibitors
10.6.2 Somatostatin
10.6.3 Ketoconazole HRA
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Glucocorticoid Receptor Inhibitors
11.6.2 Somatostatin
11.6.3 Ketoconazole HRA
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Glucocorticoid Receptor Inhibitors
12.6.2 Somatostatin
12.6.3 Ketoconazole HRA
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Glucocorticoid Receptor Inhibitors
13.6.2 Somatostatin
13.6.3 Ketoconazole HRA
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cushing's Syndrome and Acromegaly Treatment Market: Competitive Dashboard
14.2 Global Cushing's Syndrome and Acromegaly Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Bristol-Myers Squibb
14.3.4 Corcept Therapeutics
14.3.5 HRA Pharma
14.3.6 Ipsen Biopharmaceuticals
